Overview

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

Status:
Active, not recruiting

Trial end date:
2021-08-01

Target enrollment:

Participant gender:

Summary

This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.

Phase:

Phase 1

Details

Lead Sponsor:

Grupo Español de Investigación en Neurooncología

Collaborator:

Pfizer

Treatments:

Crizotinib
Temozolomide